Celgene, Nurix Collaborate For $150m Up Front

Celgene will pay Nurix Inc. $150m up front to develop and commercialize novel small molecules that modulate the ubiquitin proteasome system (UPS) in a deal that gives both companies multiple options for benefitting from joint oncology, inflammation and immunology programs.

Celgene will pay Nurix Inc. $150m up front to develop and commercialize novel small molecules that modulate the ubiquitin proteasome system (UPS) in a deal that gives both companies multiple options for benefitting from joint oncology, inflammation and immunology programs.

Harnessing the UPS, which controls protein levels within cells, to modulate protein homeostasis could lead to new treatments for cancer,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category